C-kit expression in human osteosarcoma and in vitro assays
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://www.ijcep.com/1109006A.html http://repositorio.unifesp.br/handle/11600/44032 |
Resumo: | Biologic agents targeting oncogenes have encourage researchs trying to correlate the role of tyrosine kinase in the pathogenesis of tumours. Osteosarcoma is a high grade aggressive neoplasm with poor survival. Our aim was to investigate c-kit immunoexpression, its prognostic relevance for patients with osteosarcoma, and the effect of imatinib mesylate (STI571) on proliferation and invasion of the human osteosarcoma cell line. A retrospective immunohistochemical study was performed on archival formalin-fixed paraffin-embedded specimens from 52 patients with high-grade primary osteosarcoma of extremities treated at the Pediatric Oncology Institute (IOP, GRAAC) and archived in the Department of Pathology, Federal University of Sao Paulo. Only pre-chemotherapy specimens were analyzed. Strongly stained cytoplasm and membrane cells were taken as positive. Human osteosarcoma cells from line MG-63 were incubated and the inhibitory effect of imatinib mesylate (STI571) on cell proliferation and invasion was studied. In 24 cases (46.15%), c-kit was expressed by the cells and c-kit-positive tumors exhibited lower necrosis post-chemotherapy. No correlation was found between c-kit expression and overall and disease-free survival. Imatinib mesylate decreased the rates of cell growth of osteosarcoma cells in low doses and invasion in high doses C-kit-positive tumors had worse response to chemotherapy and imatinib mesylate can play a role in blocking or decreasing the rate of growth of osteosarcoma cells, but not the invasive capacity of these neoplastic cells. These data suggested that imatinib mesylate could be a therapeutic target of strategies against osteosarcoma tumors. Further studies are necessary to confirm this indication. |
id |
UFSP_c2e6fafff21472a6be2d53ba5f2e36b7 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/44032 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
C-kit expression in human osteosarcoma and in vitro assaysOsteosarcomac-kitimmunohistochemistryin vitro assaysprognosisBiologic agents targeting oncogenes have encourage researchs trying to correlate the role of tyrosine kinase in the pathogenesis of tumours. Osteosarcoma is a high grade aggressive neoplasm with poor survival. Our aim was to investigate c-kit immunoexpression, its prognostic relevance for patients with osteosarcoma, and the effect of imatinib mesylate (STI571) on proliferation and invasion of the human osteosarcoma cell line. A retrospective immunohistochemical study was performed on archival formalin-fixed paraffin-embedded specimens from 52 patients with high-grade primary osteosarcoma of extremities treated at the Pediatric Oncology Institute (IOP, GRAAC) and archived in the Department of Pathology, Federal University of Sao Paulo. Only pre-chemotherapy specimens were analyzed. Strongly stained cytoplasm and membrane cells were taken as positive. Human osteosarcoma cells from line MG-63 were incubated and the inhibitory effect of imatinib mesylate (STI571) on cell proliferation and invasion was studied. In 24 cases (46.15%), c-kit was expressed by the cells and c-kit-positive tumors exhibited lower necrosis post-chemotherapy. No correlation was found between c-kit expression and overall and disease-free survival. Imatinib mesylate decreased the rates of cell growth of osteosarcoma cells in low doses and invasion in high doses C-kit-positive tumors had worse response to chemotherapy and imatinib mesylate can play a role in blocking or decreasing the rate of growth of osteosarcoma cells, but not the invasive capacity of these neoplastic cells. These data suggested that imatinib mesylate could be a therapeutic target of strategies against osteosarcoma tumors. Further studies are necessary to confirm this indication.Univ Fed Sao Paulo, Dept Pathol, Sao Paulo, BrazilUniv Fed Sao Paulo, IOP, GRAACC, UNIFESP,Dept Pediat, Sao Paulo, BrazilMcGill Univ, Henry C Witelson Ocular Pathol Lab, Montreal, PQ, CanadaCtr Hosp Afillie Univ Quebec, Dept Pathol, Quebec City, PQ, CanadaUniv Fed Sao Paulo, Dept Orthoped Surg, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Pathol, Sao Paulo, BrazilUniv Fed Sao Paulo, IOP, GRAACC, UNIFESP,Dept Pediat, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Orthoped Surg, Sao Paulo, BrazilWeb of ScienceE-century Publishing CorpUniversidade Federal de São Paulo (UNIFESP)McGill UnivCtr Hosp Afillie Univ QuebecMiiji, Luciana Nakao Odashiro [UNIFESP]Petrilli, Antonio Sergio [UNIFESP]Di Cesare, SebastianOdashiro, Alexandre Nakao [UNIFESP]Burnier, Miguel Noel Nascente [UNIFESP]Toledo, Silvia Regina Caminada de [UNIFESP]Garcia, Reynaldo JesusAlves, Maria Teresa de Seixas [UNIFESP]2018-06-15T17:44:18Z2018-06-15T17:44:18Z2011-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion775-781application/pdfhttp://www.ijcep.com/1109006A.htmlInternational Journal Of Clinical And Experimental Pathology. Madison: E-century Publishing Corp, v. 4, n. 8, p. 775-781, 2011.WOS000298346300006.pdf1936-2625http://repositorio.unifesp.br/handle/11600/44032WOS:000298346300006engInternational Journal Of Clinical And Experimental Pathologyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-05T09:17:51Zoai:repositorio.unifesp.br/:11600/44032Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-05T09:17:51Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
C-kit expression in human osteosarcoma and in vitro assays |
title |
C-kit expression in human osteosarcoma and in vitro assays |
spellingShingle |
C-kit expression in human osteosarcoma and in vitro assays Miiji, Luciana Nakao Odashiro [UNIFESP] Osteosarcoma c-kit immunohistochemistry in vitro assays prognosis |
title_short |
C-kit expression in human osteosarcoma and in vitro assays |
title_full |
C-kit expression in human osteosarcoma and in vitro assays |
title_fullStr |
C-kit expression in human osteosarcoma and in vitro assays |
title_full_unstemmed |
C-kit expression in human osteosarcoma and in vitro assays |
title_sort |
C-kit expression in human osteosarcoma and in vitro assays |
author |
Miiji, Luciana Nakao Odashiro [UNIFESP] |
author_facet |
Miiji, Luciana Nakao Odashiro [UNIFESP] Petrilli, Antonio Sergio [UNIFESP] Di Cesare, Sebastian Odashiro, Alexandre Nakao [UNIFESP] Burnier, Miguel Noel Nascente [UNIFESP] Toledo, Silvia Regina Caminada de [UNIFESP] Garcia, Reynaldo Jesus Alves, Maria Teresa de Seixas [UNIFESP] |
author_role |
author |
author2 |
Petrilli, Antonio Sergio [UNIFESP] Di Cesare, Sebastian Odashiro, Alexandre Nakao [UNIFESP] Burnier, Miguel Noel Nascente [UNIFESP] Toledo, Silvia Regina Caminada de [UNIFESP] Garcia, Reynaldo Jesus Alves, Maria Teresa de Seixas [UNIFESP] |
author2_role |
author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) McGill Univ Ctr Hosp Afillie Univ Quebec |
dc.contributor.author.fl_str_mv |
Miiji, Luciana Nakao Odashiro [UNIFESP] Petrilli, Antonio Sergio [UNIFESP] Di Cesare, Sebastian Odashiro, Alexandre Nakao [UNIFESP] Burnier, Miguel Noel Nascente [UNIFESP] Toledo, Silvia Regina Caminada de [UNIFESP] Garcia, Reynaldo Jesus Alves, Maria Teresa de Seixas [UNIFESP] |
dc.subject.por.fl_str_mv |
Osteosarcoma c-kit immunohistochemistry in vitro assays prognosis |
topic |
Osteosarcoma c-kit immunohistochemistry in vitro assays prognosis |
description |
Biologic agents targeting oncogenes have encourage researchs trying to correlate the role of tyrosine kinase in the pathogenesis of tumours. Osteosarcoma is a high grade aggressive neoplasm with poor survival. Our aim was to investigate c-kit immunoexpression, its prognostic relevance for patients with osteosarcoma, and the effect of imatinib mesylate (STI571) on proliferation and invasion of the human osteosarcoma cell line. A retrospective immunohistochemical study was performed on archival formalin-fixed paraffin-embedded specimens from 52 patients with high-grade primary osteosarcoma of extremities treated at the Pediatric Oncology Institute (IOP, GRAAC) and archived in the Department of Pathology, Federal University of Sao Paulo. Only pre-chemotherapy specimens were analyzed. Strongly stained cytoplasm and membrane cells were taken as positive. Human osteosarcoma cells from line MG-63 were incubated and the inhibitory effect of imatinib mesylate (STI571) on cell proliferation and invasion was studied. In 24 cases (46.15%), c-kit was expressed by the cells and c-kit-positive tumors exhibited lower necrosis post-chemotherapy. No correlation was found between c-kit expression and overall and disease-free survival. Imatinib mesylate decreased the rates of cell growth of osteosarcoma cells in low doses and invasion in high doses C-kit-positive tumors had worse response to chemotherapy and imatinib mesylate can play a role in blocking or decreasing the rate of growth of osteosarcoma cells, but not the invasive capacity of these neoplastic cells. These data suggested that imatinib mesylate could be a therapeutic target of strategies against osteosarcoma tumors. Further studies are necessary to confirm this indication. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-01-01 2018-06-15T17:44:18Z 2018-06-15T17:44:18Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://www.ijcep.com/1109006A.html International Journal Of Clinical And Experimental Pathology. Madison: E-century Publishing Corp, v. 4, n. 8, p. 775-781, 2011. WOS000298346300006.pdf 1936-2625 http://repositorio.unifesp.br/handle/11600/44032 WOS:000298346300006 |
url |
http://www.ijcep.com/1109006A.html http://repositorio.unifesp.br/handle/11600/44032 |
identifier_str_mv |
International Journal Of Clinical And Experimental Pathology. Madison: E-century Publishing Corp, v. 4, n. 8, p. 775-781, 2011. WOS000298346300006.pdf 1936-2625 WOS:000298346300006 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
International Journal Of Clinical And Experimental Pathology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
775-781 application/pdf |
dc.publisher.none.fl_str_mv |
E-century Publishing Corp |
publisher.none.fl_str_mv |
E-century Publishing Corp |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268283636940800 |